156 related articles for article (PubMed ID: 33214335)
1. CD49d and CD49e induce cell adhesion-mediated drug resistance through the nuclear factor-κB pathway in Burkitt lymphoma.
Takeda T; Tsubak M; Genno S; Matsuda T; Yamamoto Y; Ueda E; Imano M; Satou T; Nishida S
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33214335
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
3. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
4. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells.
Nakagawa Y; Nakayama H; Nagata M; Yoshida R; Kawahara K; Hirosue A; Tanaka T; Yuno A; Matsuoka Y; Kojima T; Yoshitake Y; Hiraki A; Shinohara M
Int J Oncol; 2014 Apr; 44(4):1376-84. PubMed ID: 24452447
[TBL] [Abstract][Full Text] [Related]
6. Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells.
Zeller W; Kröger N; Berger J; Krueger W; Dierlamm J; Stockschläder M; Gutensohn K; Hossfeld DK; Zander AR
J Hematother Stem Cell Res; 1999 Oct; 8(5):539-46. PubMed ID: 10791904
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Zou P; Kawada J; Pesnicak L; Cohen JI
J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.
Mraz M; Zent CS; Church AK; Jelinek DF; Wu X; Pospisilova S; Ansell SM; Novak AJ; Kay NE; Witzig TE; Nowakowski GS
Br J Haematol; 2011 Oct; 155(1):53-64. PubMed ID: 21749361
[TBL] [Abstract][Full Text] [Related]
9. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.
Richter-Larrea JA; Robles EF; Fresquet V; Beltran E; Rullan AJ; Agirre X; Calasanz MJ; Panizo C; Richter JA; Hernandez JM; Roman-Gomez J; Prosper F; Martinez-Climent JA
Blood; 2010 Oct; 116(14):2531-42. PubMed ID: 20570860
[TBL] [Abstract][Full Text] [Related]
10. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
11. β-elemene against Burkitt's lymphoma via activation of PUMA mediated apoptotic pathway.
Hu T; Gao Y
Biomed Pharmacother; 2018 Oct; 106():1557-1562. PubMed ID: 30119230
[TBL] [Abstract][Full Text] [Related]
12. Chemo-sensitizing effects of EP4 receptor-induced inactivation of nuclear factor-κB.
Gobec M; Prijatelj M; Delić J; Markovič T; Mlinarič-Raščan I
Eur J Pharmacol; 2014 Nov; 742():81-8. PubMed ID: 25218986
[TBL] [Abstract][Full Text] [Related]
13. Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi.
Zhang J; Li B; Wu H; Ou J; Wei R; Liu J; Cai W; Liu X; Zhao S; Yang J; Zhou L; Liu S; Liang A
Tumour Biol; 2016 Jan; 37(1):531-9. PubMed ID: 26227222
[TBL] [Abstract][Full Text] [Related]
14. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
15. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
16. Japonicone A suppresses growth of Burkitt lymphoma cells through its effect on NF-κB.
Li X; Yang X; Liu Y; Gong N; Yao W; Chen P; Qin J; Jin H; Li J; Chu R; Shan L; Zhang R; Zhang W; Wang H
Clin Cancer Res; 2013 Jun; 19(11):2917-28. PubMed ID: 23620411
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells.
Tabata M; Tsubaki M; Takeda T; Tateishi K; Tsurushima K; Imano M; Satou T; Ishizaka T; Nishida S
BMC Complement Med Ther; 2020 Mar; 20(1):84. PubMed ID: 32171300
[TBL] [Abstract][Full Text] [Related]
18. Effects of digoxin on cell cycle, apoptosis and NF-κB pathway in Burkitt's lymphoma cells and animal model.
Wang T; Xu P; Wang F; Zhou D; Wang R; Meng L; Wang X; Zhou M; Chen B; Ouyang J
Leuk Lymphoma; 2017 Jul; 58(7):1673-1685. PubMed ID: 28084852
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic determinants of resistance to etoposide regulation of Bcl-X(L) and Bax by tumor microenvironmental factors.
Taylor ST; Hickman JA; Dive C
J Natl Cancer Inst; 2000 Jan; 92(1):18-23. PubMed ID: 10620629
[TBL] [Abstract][Full Text] [Related]
20. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Jazirehi AR; Huerta-Yepez S; Cheng G; Bonavida B
Cancer Res; 2005 Jan; 65(1):264-76. PubMed ID: 15665303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
